Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.245
+0.055 (4.62%)
At close: Jun 23, 2026, 4:00 PM EDT
1.240
-0.005 (-0.40%)
After-hours: Jun 23, 2026, 4:10 PM EDT

Metagenomi Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4761135---
Market Cap Growth
-27.81%-54.88%----
Enterprise Value
-54.29-59.2-67.45000
Last Close Price
1.251.623.61---
PS Ratio
2.092.422.58---
PB Ratio
0.340.380.58---
P/TBV Ratio
0.340.380.51---
EV/Sales Ratio
--2.35-1.29---
EV/EBITDA Ratio
-0.650.81---
EV/EBIT Ratio
-0.620.76---
EV/FCF Ratio
-0.660.60---
Debt / Equity Ratio
0.240.220.170.210.061.10
Debt / FCF Ratio
----1.182.29
Net Debt / Equity Ratio
-0.73-0.76-0.861.644.621.82
Net Debt / EBITDA Ratio
1.151.332.433.008.012.51
Net Debt / FCF Ratio
1.151.341.812.20-21.82-2.77
Asset Turnover
0.110.090.150.110.060.00
Quick Ratio
6.237.026.693.977.494.30
Current Ratio
6.437.226.914.047.564.33
Return on Equity (ROE)
-57.96%-44.67%-34.69%-28.04%-27.62%-48.79%
Return on Assets (ROA)
-44.31%-35.17%-24.09%-22.83%-17.05%-16.86%
Return on Invested Capital (ROIC)
-134.14%-116.10%-70.03%-78.20%-68.41%-44.88%
Return on Capital Employed (ROCE)
-49.80%-39.56%-30.48%-23.72%-18.49%-20.50%
Buyback Yield / Dilution
-1.06%-12.79%-870.10%-0.15%0.15%-
Total Shareholder Return
-1.06%-12.79%-870.10%-0.15%0.15%-
SEC Filings: 10-K · 10-Q